Polpharma Secures Government Funding For Complex Inhalable And Injectable Generics

One Grant Will Be Used To Develop A Generic Polypeptide

The Polish player has won two grants sourced from the government’s National Recovery and Resilience Plan, which has given out $28.1m in funding in the latest round.

Warsaw capitol of Poland. Copy Space available. - Image
Polish Regulator URPL Has Approved Two Switches • Source: Shutterstock

The drug manufacturer Polpharma has won two grants from the Polish Medical Research Agency aimed at the development of new generics for respiratory diseases and type 2 diabetes.

Specifically, the Polish generic drug maker received a grant for the development of inhalable complex generic drugs for the treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

More from Generics Bulletin

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By 

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By 

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.